Safety of lecanemab in real-world patients with Alzheimer's disease: a prospective, observational case series supported by FAERS signal analysis. (PubMed, Front Neuroinform) - Oct 18, 2026 - "Particular clinical vigilance is required regarding the occurrence of AEs within the first two months of lecanemab initiation. Notably, ARIA (including both ARIA-E and ARIA-H) can occur at any phase during the treatment course."
Journal • Observational data • Real-world evidence • Alzheimer's Disease • Cardiovascular • CNS Disorders • Hematological Disorders • Pain
|
|
ErHao Bao; Haixia Ji; Xingqi Wu; Yang Yang
|